零售药店转型

Search documents
关店潮来了!零售药店谋变
Zheng Quan Shi Bao Wang· 2025-08-21 02:56
轰轰烈烈扩张多年的零售药店行业,在2025年进入负增长。供给过剩的格局之下,今年一季度,3000家 药店关闭退出市场,相比全行业近70万家的存量,这或许只是一个开始。 "这两年,关店将是一个常态,我们有可能回到2018年,当时全行业是50多万家药店。"益丰药房 (603939)董事长高毅在近期召开的2025西普会(CPEO,健康产业生态大会)上表示。 中康科技商用数据事业部总经理廖洪惠介绍,零售药店增长的拐点在2024年四季度已经出现,至2025年 第一季度,药店总量已经跌破了70万家大关,正式进入了负增长阶段。2025年第一季度,全国药店净减 少约3000家。而在过去的7年里,中国零售药店数量增长幅度为50%。 零售药店规模由盛转衰,缘于蛋糕的缩小。2024年全国药品全终端市场规模2.03万亿元,同比增幅仅 0.9%,廖洪惠预判,今年全终端的药品销售规模预测为1.97万亿元,将出现近年来的首次下跌,线下零 售药店环节因客流的减少而承受更大压力。非药市场中,去年各品类销售全线下跌,也压制了零售药店 的业绩表现。 缩小的蛋糕,加大了竞争激烈程度,挤压了利润空间。2024年,8家上市药房营收增长中位数仅4.7%, ...
闭店潮下零售药店谋变 靠前服务拓展价值点
Zheng Quan Shi Bao· 2025-08-20 18:30
Core Viewpoint - The retail pharmacy industry in China is entering a phase of negative growth by 2025, with a significant number of store closures and a shift in focus towards health services rather than just product sales [1][2][3] Industry Overview - The retail pharmacy sector has seen a 50% increase in store numbers over the past seven years, but the total number of pharmacies has now dropped below 700,000, marking the beginning of negative growth [2][3] - In Q1 2025, approximately 3,000 pharmacies closed, indicating a trend that may continue as the market contracts [2][3] Market Dynamics - The overall market size for pharmaceuticals in China is projected to decline for the first time, with a forecasted sales figure of 1.97 trillion yuan in 2024, reflecting a year-on-year decrease [2] - The competition among pharmacies has intensified due to a shrinking market, leading to a median revenue growth of only 4.7% among eight listed pharmacy companies, while median profit has decreased by 32.9% [2] Strategic Responses - Some retail pharmacies are slowing down their expansion plans, while others are increasing their franchise operations to boost market share [3] - The concentration of the top 100 pharmacy chains has risen to 53%, indicating a trend towards consolidation in the industry [3] Opportunities for Innovation - Despite declines in various product categories, the sales of biopharmaceuticals have surged by 17.7%, suggesting a potential growth area for the industry [3][4] - The DTP (Direct to Patient) market is expanding, with a projected sales growth of 17.2% in 2024, highlighting a shift towards more personalized patient care [4][5] Collaboration and Diversification - There is a growing interest from innovative pharmaceutical companies to collaborate with retail pharmacies, particularly in the DTP sector, to enhance patient services [5][6] - Retail pharmacies are exploring diversification into beauty and health products, with potential market opportunities reaching trillions [6][7] Future Outlook - The industry is expected to evolve from a product-centric model to a health-centric approach, driven by increasing health demands and innovations in drug supply [7][8] - The existing network of nearly 700,000 pharmacies provides a unique opportunity to enhance health service delivery across the country [7]
老百姓大药房4.4亿减持,揭开连锁药店的“虚火”与真相
阿尔法工场研究院· 2025-05-15 03:47
Core Viewpoint - The retail pharmacy industry is facing significant challenges, including profitability imbalance, increased compliance costs, and competition from new business models, leading to an impending industry reshuffle [1][22]. Financial Performance - The major retail pharmacy chain, Lao Bai Xing Pharmacy, announced a substantial share reduction plan of up to 22.8 million shares, amounting to 440 million yuan, following a report showing a decline in revenue and net profit by 0.36% and 44.13% respectively [2][4]. - The top six listed retail pharmacy chains have experienced a slowdown in revenue growth, with most reporting single-digit growth rates in 2024, and net profits declining by 20% to 240% year-on-year, except for Yi Feng Pharmacy which saw an 8% increase [4][5]. Industry Trends - The "ten thousand store era" has seen a rapid increase in the number of retail pharmacies, with over 39,000 closures expected in 2024, indicating a saturated market [5][6]. - The average revenue per square meter for Lao Bai Xing Pharmacy has decreased from 59.2 yuan/square meter in 2020 to 47 yuan/square meter in 2024, highlighting the pressure on profitability due to high competition [6][8]. Regulatory Environment - The suspension of new approvals for medical insurance designated pharmacies has limited growth opportunities for chains reliant on this model, with Lao Bai Xing having 9,158 such stores, covering 93.03% of its direct stores [10][11]. - Increased regulatory scrutiny and compliance costs are further straining the operational efficiency of retail pharmacies [8][10]. Strategic Shifts - Retail pharmacies are attempting to diversify their product offerings beyond pharmaceuticals to include health products, beauty items, and other non-pharmaceutical goods, but face challenges in establishing competitive advantages in these mature markets [12][14]. - The shift towards a more professional health service model is seen as a potential core competitive advantage for retail pharmacies in the future [14][20]. Competitive Landscape - The competition is no longer limited to traditional pharmacies but includes supermarkets, beauty stores, and B2C platforms, necessitating a transformation in business models [20][21]. - The industry is expected to undergo a reshuffle, with those who can effectively transition to diversified, professional, and online models likely to capture the next wave of growth [21][22].